Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 5 | 2 |
| List of Tables | 6 | 1 |
| List of Figures | 6 | 1 |
| Introduction | 7 | 3 |
| Introduction | 7 | 1 |
| High Levels of Product Diversification in a Highly Competitive Market Environment | 7 | 1 |
| Inconsistent Clinician Prescribing Preferences | 7 | 1 |
| Ongoing Market Shift Towards Abuse-Resistant Product Formulations | 8 | 1 |
| Increasingly Vocal Physician Associations Raise Concerns About Extent of Opioid Abuse | 9 | 1 |
| Full Commercial Potential of Transdermal Patches May Have Yet to be Fully Exploited | 9 | 1 |
| Overview of Currently Marketed Products | 10 | 7 |
| Major Marketed Products | 10 | 1 |
| Oxycontin | 10 | 1 |
| Exalgo | 10 | 1 |
| Onsolis | 10 | 1 |
| Duragesic | 11 | 1 |
| Opana ER | 11 | 1 |
| Vicodin CR | 11 | 1 |
| Dolophine Hydrochloride | 11 | 1 |
| Oxecta | 11 | 1 |
| Actiq | 12 | 1 |
| Embeda | 12 | 1 |
| Kadian | 12 | 1 |
| Avinza | 12 | 1 |
| Market Drivers and Barriers | 13 | 1 |
| Drivers | 14 | 1 |
| In the Medium Term, New Abuse-Resistant Formulations of ER Opioids are Expected to Act as Moderate Drivers in a Largely Stagnant Market | 14 | 1 |
| Variable Physician Preferences for Opioid Compounds and Different Formulations Suggest a Sizable Opportunity for Branded Products | 14 | 1 |
| High Success Rate for Marketing Approvals | 14 | 1 |
| Growing Patient Population in Developed Markets | 14 | 1 |
| Barriers | 15 | 1 |
| Growing Regulatory Body Intervention and Increasing Concerns in the Medical Community Regarding Abuse are Expected to Curb Medically Unwarranted Opioid Prescribing | 15 | 1 |
| Market Saturation with ER and Abuse-Resistant Formulations is Expected to Result in High Competition | 15 | 1 |
| Lack of Innovative Products in the Pipeline | 15 | 1 |
| Highly Competitive Pricing | 16 | 1 |
| Pipeline Analysis | 17 | 11 |
| Introduction | 17 | 3 |
| Opioid Compounds in the Developmental Pipeline | 20 | 3 |
| Distribution by Route of Administration | 23 | 3 |
| Promising Pipeline Products | 26 | 1 |
| ARX-01, AcelRX Pharmaceuticals | 26 | 1 |
| ALO-02, Pfizer | 26 | 1 |
| Zohydro ER, Zogenix | 26 | 1 |
| ELI-216, Elite Pharmaceuticals | 27 | 1 |
| BEMA Buprenorphine | 27 | 1 |
| CEP-33237, Cephalon | 27 | 1 |
| Deals Analysis | 28 | 12 |
| Overview: | 28 | 1 |
| M&As by Year | 28 | 1 |
| M&As by Value | 29 | 1 |
| Major M&As | 30 | 1 |
| Takeda Completes Acquisition of Nycomed International for $13.7 Billion | 30 | 1 |
| Teva Pharmaceuticals Completes Acquisition of Cephalon for $6.8 Billion | 30 | 1 |
| Pfizer Acquires King Pharmaceuticals for $3.6 Billion | 30 | 1 |
| Dainippon Sumitomo Pharma Completes Acquisition of Sepracor for $2.6 Billion | 30 | 1 |
| Pfizer Acquires Rinat Neuroscience | 31 | 1 |
| Sun Pharmaceutical Acquires Controlling Stake in Taro Pharmaceutical Industries | 31 | 1 |
| Kyowa Hakko Kirin Completes Acquisition of ProStrakan Group | 31 | 1 |
| Sosei Acquires Arakis | 31 | 1 |
| Hospira Completes Acquisition of Javelin Pharmaceuticals | 32 | 1 |
| Endo Pharmaceuticals Completes Acquisition of Penwest Pharmaceuticals | 32 | 1 |
| Licensing Agreements | 33 | 1 |
| Licensing Agreements by Year | 33 | 1 |
| Licensing Agreements by Value | 34 | 1 |
| Major Licensing Agreements | 35 | 1 |
| Amgen Enters into Licensing Agreement with Ortho-McNeil-Janssen | 35 | 1 |
| Allergan Enters into Licensing Agreement with Bristol-Myers Squibb | 35 | 1 |
| Eli Lilly Enters into Licensing Agreement with Glenmark Pharmaceuticals | 35 | 1 |
| Sanofi Enters into Licensing Agreement with Glenmark Pharmaceuticals | 35 | 1 |
| GW Pharmaceuticals Enters into Licensing Agreement with Otsuka Pharmaceutical | 36 | 1 |
| Idea Enters into Licensing Agreement with Alpharm | 36 | 1 |
| BioDelivery Sciences Enters into Licensing Agreement with Endo Pharmaceuticals for BEMA Buprenorphine | 36 | 1 |
| Labopharm Enters into Licensing and Distribution Agreement with Purdue Pharma | 37 | 1 |
| Endo Pharmaceuticals Enters into Licensing Agreement with Novartis | 37 | 1 |
| Co-Development Agreements | 38 | 1 |
| Deals by Year | 38 | 1 |
| Major Co-Development Deals | 39 | 1 |
| GlaxoSmithKline Enters Into an Agreement with XenoPort | 39 | 1 |
| King Pharmaceuticals Enters into Co-Development Agreement with Pain Therapeutics | 39 | 1 |
| AstraZeneca Enters into an Agreement with Pozen | 39 | 1 |
| Appendix | 40 | 4 |
| Abbreviations | 40 | 1 |
| Bibliography | 41 | 1 |
| Research Methodology | 41 | 2 |
| Coverage | 41 | 1 |
| Secondary Research | 42 | 1 |
| Primary Research | 42 | 1 |
| Pipeline Analysis | 42 | 1 |
| Expert Panel Validation | 42 | 1 |
| Contact Us | 43 | 1 |
| Disclaimer | 43 | 1 |